ProKidney finished the enrollment that decides whether rilparencel earns a shot at accelerated approval, and the equity is now a waiting game against a cash clock that expires at almost the same moment as the data. The Winston-Salem cell-therapy developer closed the roughly 320-patient cohort that feeds the registrational PROACT 1 surrogate analysis. Management points to a second quarter 2027 filtration-slope readout as the next real verdict. That pairing of a completed enrollment event with a runway that only stretches into mid-2027 is the entire investment case in miniature.
The cash story is less forgiving than the clinical headline. Combined cash and marketable securities stood at $182 million at the June close, down from $225 million one quarter earlier. Operating cash burn absorbed $82 million in the first half, so the remaining pile funds operations only into mid-2027 if the current spend rate holds. Management still writes that existing liquidity is not enough for the twelve months after the August statements were issued, which is the formal going-concern language. An unused Jefferies at-the-market facility with about $175 million of remaining capacity is the obvious bridge, and it is also the dilution that the market already discounts.
The strongest evidence that the program is real is not the second-quarter print. It is the July 2025 Type B confirmation that annualized estimated glomerular filtration rate slope, the standard blood-test measure of how fast kidneys filter, can support an accelerated Biologics License Application, plus the Phase Two REGEN-007 finding that bilateral injections improved the annual decline by roughly five milliliters in the protocol that the registrational study copies. The counterargument is that those Phase Two arms were small, open-label, and compared each patient to that patient's own pre-injection slope rather than to a sham control. The question the next year resolves is whether ProKidney can fund the gap to the readout without issuing so much stock that a positive print barely matters.